Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease : an expert review
Introduction: The current recommendations of chronic obstructive pulmonary disease (COPD) suggest to escalate from inhaled corticosteroid/long-acting β2-adrenoceptor agonist (ICS/LABA) treatment to triple therapy in patients experiencing persistent breathlessness, exercise limitation, or exacerbation. The addition of an ICS to LABA/long-acting muscarinic antagonist (LAMA) combination is recommended for frequently exacerbating patients with high levels of blood eosinophils. Nowadays, three triple therapies have been approved as fixed-dose combinations (FDCs) for the treatment of COPD: beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FOR/GLY), fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), and budesonide/glycopyrronium bromide/formoterol fumarate (BUD/GLY/FOR).Areas covered: This narrative review evaluates the efficacy and safety profile of triple FDC therapy for the treatment of COPD, by evaluating the data originating from pivotal randomized-controlled trials (RCTs).Expert opinion: The currently approved triple FDCs exert a protective effect against the risk of COPD exacerbation compared to ICS/LABA and LABA/LAMA, with some concerns regarding the risk of pneumonia for some specific FDCs. Since the assessed RCTs were characterized by important confounders, the obtained results should be interpreted with caution. Indeed, FDCs provide advantages in terms of improved adherence to treatment and lower errors in COPD management; however, direct head-to-head comparisons are needed to establish real differences between the currently approved triple FDCs.
| Errataetall: |
CommentIn: Expert Opin Pharmacother. 2021 May;22(7):939-941. - PMID 33655817 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Expert opinion on pharmacotherapy - 22(2021), 5 vom: 10. Apr., Seite 611-620 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ritondo, Beatrice Ludovica [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 27.04.2021 Date Revised 12.07.2021 published: Print-Electronic CommentIn: Expert Opin Pharmacother. 2021 May;22(7):939-941. - PMID 33655817 Citation Status MEDLINE |
|---|
| doi: |
10.1080/14656566.2020.1845314 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316997838 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316997838 | ||
| 003 | DE-627 | ||
| 005 | 20231225162312.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14656566.2020.1845314 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1056.xml |
| 035 | |a (DE-627)NLM316997838 | ||
| 035 | |a (NLM)33131340 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ritondo, Beatrice Ludovica |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease |b an expert review |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2021 | ||
| 500 | |a Date Revised 12.07.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Expert Opin Pharmacother. 2021 May;22(7):939-941. - PMID 33655817 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Introduction: The current recommendations of chronic obstructive pulmonary disease (COPD) suggest to escalate from inhaled corticosteroid/long-acting β2-adrenoceptor agonist (ICS/LABA) treatment to triple therapy in patients experiencing persistent breathlessness, exercise limitation, or exacerbation. The addition of an ICS to LABA/long-acting muscarinic antagonist (LAMA) combination is recommended for frequently exacerbating patients with high levels of blood eosinophils. Nowadays, three triple therapies have been approved as fixed-dose combinations (FDCs) for the treatment of COPD: beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FOR/GLY), fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), and budesonide/glycopyrronium bromide/formoterol fumarate (BUD/GLY/FOR).Areas covered: This narrative review evaluates the efficacy and safety profile of triple FDC therapy for the treatment of COPD, by evaluating the data originating from pivotal randomized-controlled trials (RCTs).Expert opinion: The currently approved triple FDCs exert a protective effect against the risk of COPD exacerbation compared to ICS/LABA and LABA/LAMA, with some concerns regarding the risk of pneumonia for some specific FDCs. Since the assessed RCTs were characterized by important confounders, the obtained results should be interpreted with caution. Indeed, FDCs provide advantages in terms of improved adherence to treatment and lower errors in COPD management; however, direct head-to-head comparisons are needed to establish real differences between the currently approved triple FDCs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Chronic obstructive pulmonary disease | |
| 650 | 4 | |a fixed-dose combinations | |
| 650 | 4 | |a inhaled corticosteroids | |
| 650 | 4 | |a long-acting muscarinic receptor antagonists | |
| 650 | 4 | |a long-acting β2-adrenoceptor agonists | |
| 650 | 4 | |a triple therapy | |
| 650 | 7 | |a Adrenergic beta-2 Receptor Agonists |2 NLM | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Muscarinic Antagonists |2 NLM | |
| 650 | 7 | |a Glycopyrrolate |2 NLM | |
| 650 | 7 | |a V92SO9WP2I |2 NLM | |
| 650 | 7 | |a Formoterol Fumarate |2 NLM | |
| 650 | 7 | |a W34SHF8J2K |2 NLM | |
| 700 | 1 | |a Puxeddu, Ermanno |e verfasserin |4 aut | |
| 700 | 1 | |a Calzetta, Luigino |e verfasserin |4 aut | |
| 700 | 1 | |a Cazzola, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Rogliani, Paola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on pharmacotherapy |d 1999 |g 22(2021), 5 vom: 10. Apr., Seite 611-620 |w (DE-627)NLM111602130 |x 1744-7666 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:5 |g day:10 |g month:04 |g pages:611-620 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14656566.2020.1845314 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 5 |b 10 |c 04 |h 611-620 | ||